Windex celebrates 75th birthday
RACINE, Wis. — SC Johnson’s glass cleaner brand is marking a milestone: its 75th birthday.
To celebrate its more than seven decades in the market, Windex is looking back through history and inviting families to share their "traditions and shining moments" on the brand’s Facebook page. As part of the campaign, Windex has enlisted three moms to spark conversations and inspire new ideas through the brand’s Facebook page, Twitter and their own personal blogs. The goal: to encourage others to talk about their traditions and also offer families resources to help bring these traditions to life.
"The Windex brand has been a part of the American household for 75 years, which we think creates a nice connection between timeless family traditions with how the brand’s heritage has evolved," said Kelly Semrau, SC Johnson SVP global corporate affairs, communication and sustainability. "Few brands have stood the test of time, which is why we want to hear from the families who have helped make the Windex brand the icon it is today."
Water-Jel plans to build burn care at retail; Herb Baer to lead efforts
CARLSTADT, N.J. — Water-Jel Technologies last month named Herb Baer to the post of EVP North America. Well-known among military and industrial users, the company plans to expand first-degree burn aftercare at retail in the coming year, Baer told Drug Store News.
The company recently launched Burn Jel Plus, a thick gel that salves minor burn injuries containing vitamin E, tea tree oil and 2.5% lidocaine, into the consumer market.
Three more burn treatment products will be launched in the coming year, Baer said. That includes Water-Jel Burn Dressings, a gel-soaked dressing for larger skin surfaces; Water-Jel Unburn, a sunburn aftercare solution; and Muscle Jel, a topical analgesic already in use across several professional markets. The company also has contract manufacturing capabilities across a range of first-aid products, Baer added.
Baer joined Water-Jel from Fuji Film in 2008 as VP marketing, and was later promoted to SVP and chief marketing and sales officer.
Study: No evidence to support off-label prescribing of atypical antipsychotics
ROCKVILLE, Md. — A new report from the Department of Health and Human Services’ Agency for Healthcare Research and Quality found little evidence to support the use of atypical antipsychotic drugs for uses other than those for which they have official approval.
The report, published in the Sept. 28 issue of the Journal of the American Medical Association, found that though atypical antipsychotic medications are effective in treating schizophrenia, bipolar disorder and sometimes depression, there was no evidence that they could be used to treat substance abuse problems, eating disorders or insomnia. The report is an update of a report from 2007 that found some evidence that atypical antipsychotics could work for such conditions as dementia, anxiety disorder and obsessive-compulsive disorder.
"While atypical antipsychotic medications are not for everyone, many patients who suffer from psychiatric conditions have found these drugs to be very helpful," AHRQ director Carolyn Clancy said. "However, their off-label use, while in some cases beneficial, is of concern because we just don’t know enough about their effectiveness and safety for multiple behavioral conditions."
The Food and Drug Administration has approved nine atypical antipsychotics, including AstraZeneca’s Seroquel (quetiapine), Johnson & Johnson’s Risperdal (risperidone) and Bristol-Myers Squibb’s and Otsuka’s Abilify (aripiprazole).